Clinical Oncology Next-generation Sequencing Market is estimated to be worth around US$ 449.4 Mn in 2022

Next-generation sequencing refers to the identification of the nucleotides of DNA base pairs for the diagnosis of various diseases. Oncology is one of the important applications of next-generation sequencing. It is an advanced and faster method of sequencing. Clinical oncology next-generation sequencing includes kits & reagents, services, sequencing platforms, and sequencing products. The kits and reagents used for sequencing are expected to witness significant growth in the overall market.

North America is expected to be a prominent region in the global clinical oncology next-generation sequencing market owing to the presence of well-developed healthcare infrastructure and numerous technological advancements in the region. North America and Europe are expected to witness a significant growth rate in the clinical oncology next-generation sequencing market.

Synthesis Sequencing Technology to Hold a Major Market Value Share

Based on the technology, the clinical oncology next-generation sequencing market has been segmented into pyro sequencing, sequencing by synthesis (SBS), and Single-Molecule Real-Time Sequencing (SMRT), nanopore sequencing, ligation sequencing, and reversible dye termination sequencing. Synthesis sequencing is however expected to hold a significant share in the clinical oncology next-generation sequencing market.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9543

Ion semiconductor sequencing is a method of DNA sequencing in which hydrogen ions are detected based on the polymerisation of DNA. Pyro-sequencing includes identifying the order of nucleotides in DNA based on the “sequencing by synthesis” principle, in which the sequencing is performed with the help of DNA polymerase. SBS is a technique used to determine the series of base pairs in DNA, which also known as DNA is sequencing.

There are various applications associated with clinical oncology next-generation treatment market. They include whole tumor genome sequencing, whole tumour exome sequencing, targeted tumour genome profiling, tumour transcriptome sequencing, tumour-normal comparisons, and other applications. Targeted tumor genome profiling is expected to hold a large share of the clinical oncology next-generation treatment market.

On the basis of end user, the clinical oncology next-generation sequencing market has been segmented into hospital laboratories, clinical research organisations, diagnostic laboratories, and others. Clinical research laboratories are expected to hold a large revenue share in the clinical oncology next-generation sequencing market.

Apart from the factors driving the clinical oncology next-generation sequencing market, there are few factors that are likely to hinder the overall growth of the clinical oncology next-generation sequencing market, such as high costs associated with the establishment of sequencing platforms, low quality of outsourcing services, and inadequate availability of sequencing platforms in some regional markets.

On the other hand, increasing biomedical research using clinical oncology, increasing government funding for life science projects, substantial decline in the prices of sequencing, and technological advancements in the field of sequencing are some of the major factors driving the growth of the clinical oncology next-generation sequencing market.

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-9543

Tier 1 Companies Hold Nearly 3/5th Share of Global Market Value

The report tracks some of the key companies operating in the clinical oncology next-generation sequencing market such as QIAGEN N.V., Thermo Fisher Scientific., Pacific Biosciences of California, Inc., F. Hoffmann-La Roche Ltd Oxford Nanopore Technologies, Ltd., Takara Bio, Inc., Illumina Inc., PerkinElmer Inc.and Agilent Technologies, Inc. Thermo Fischer Scientific, Oxford Nanopore Technologies Ltd., and Illumina are expected to hold a signficant share of the clinical oncology next-generation sequencing market. These first tier companies hold a share of approximately 60% in the clinical oncology next-generation sequencing market.

CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET TAXONOMY

The global clinical oncology next generation sequencing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.

By Product

• Sequencing Platforms
• Sequencing Products
• Kits and Reagents
• Services

By Technology

• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing (SBS)
• Real Time Sequencing (SMRT)
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano-Pore Sequencing

For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-9543

By Application

• Whole Tumor Genome Sequencing
• Whole Tumor Exome Sequencing
• Targeted Tumor Genome Profiling
• Tumor Transcriptome Sequencing
• Tumor-normal Comparisons
• Others

By End User

• Hospital Laboratories
• Clinical Research Organizations
• Diagnostic Laboratories
• Others

Explore FMI’s Extensive ongoing Coverage on Healthcare Domain

Tissue Sealants and Tissue Adhesive Market Analysis : The tissue sealants and tissue adhesive market is anticipated to register a CAGR of 8.4% during the forecast period, up from US$ 1,509.6 Mn in 2021 to reach a valuation of US$ 2,876.9 Mn by 2027.

Orthopedic Prosthetic Devices Market Demand : The orthopedic prosthetic devices market is projected to register a CAGR of 4.7% during the forecast period, up from US$ 1.9 Bn in 2019 to reach a valuation of US$ 2.8 Bn by 2027. 

Artificial Pancreas Device System Market Forecast : During the forecast period, the artificial pancreas device system market is expected to advance at a rapid pace with a CAGR of 18.2%.

Therapeutic Drug Monitoring Market Growth : The therapeutic drug monitoring market is projected to record a CAGR of 9.7% during the forecast period, up from US$ 1.5 Bn in 2020 to reach a valuation of US$ 2.9 Bn by 2026.

China Spinal Fusion Market Technology : The China spinal fusion market is expected to register double-digit growth during the forecast period.

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs